Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports

View Johnson & Johnson's Q3 Earnings Report

FiercePharma says: Market reaction to Johnson & Johnson's earnings announcement reflects an overall worry about cost-cutting versus sales growth. Yes, J&J beat expectations, posting earnings of $1.20 per share, about 7 cents higher than analysts had estimated. But third-quarters sales came in at $15.1 billion, which fell short of those same estimates. At press time, the stock had fallen 2.62 percent, or $1.64, to $60.89. Read more of our coverage here...

Highlights:

  • Sales of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
  • EPS of $1.20 increased 2.6% Versus 2008 Third Quarter

Check out J&J's current earnings estimates from CNN Money

J&J's Website: http://www.jnj.com/connect/

Johnson & Johnson Q3 Results - Q3 Top Pharma Company Earnings Reports
Read more on

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.